Schneider F, Meziani F, Chartier C, Alt M, Jaeger A
Lancet. 2002 Mar 9;359(9309):852-3. doi: 10.1016/S0140-6736(02)07922-9.
We report on the occurrence of a rare and as yet unforseeable adverse reaction to treatment with celecoxib, a cyclooxygenase-2 (COX-2) selective, non-steroidal, anti-inflammatory drug. A previously healthy adult suffered fatal acute multiple organ failure presumably after diffuse allergic vasculitis with diffuse necrotic purpura. Although no conclusive proof is available, such a reaction could have been triggered by at least one of two mechanisms: an allergic reaction linked to the chemical structure of celecoxib; or an interaction of the drug with synthesis of endothelial eiconasoids leading to an imbalance between vasoactive end products, resulting in widespread rise to local thrombosis.
我们报告了一起使用塞来昔布(一种环氧化酶-2(COX-2)选择性非甾体抗炎药)治疗后出现罕见且不可预见的不良反应的事件。一名先前健康的成年人在发生弥漫性过敏性血管炎伴弥漫性坏死性紫癜后,可能死于急性多器官功能衰竭。尽管尚无确凿证据,但这种反应可能由以下两种机制中的至少一种引发:与塞来昔布化学结构相关的过敏反应;或药物与内皮类二十烷酸合成的相互作用,导致血管活性终产物之间失衡,从而引发广泛的局部血栓形成。